Nanoform – Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act
Nanoform Finland Plc | Company Release | October 16, 2025…
Nanoform Outlicenses Nanoencorafenib and Signs Development and Commercialisation Agreement with A.forall and IMGA
Nanoform Finland Plc | Press Release | October 14, 2025…
Nanoform Expands Commercial Presence in Asia with A&LS Pharma in South Korea
Nanoform Finland Plc | Press Release | September 30, 2025…
Nanoform Q3 2025 report day set for November 12th, 2025
Nanoform Finland Plc | Press Release | September 26, 2025…
Results of Nanoform Collaborative Study to be Presented at US Drug Delivery & Formulation (DDF) Summit
Nanoform Finland Plc | Press Release | September 11, 2025…
Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results
Nanoform Finland Plc | Company Release | August 21, 2025…
Invitation to Nanoform’s Q2 2025 Report Presentation
Nanoform Finland Plc | Press Release | August 07, 2025…
Nanoform Secures €5 Million R&D Loan from Business Finland to Advance Clinical Development of Nanoapalutamide
Nanoform Finland Plc | Press Release | June 19, 2025…
Nanoform Finland Plc – Manager’s Transactions – Jeanne Thoma
Nanoform Finland Plc | Company Release | June 17, 2025…
Nanoform Finland Plc – Manager’s Transactions – Miguel Calado
Nanoform Finland Plc | Company Release | June 17, 2025…
Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström
Nanoform Finland Plc | Company Release | June 17, 2025…
Share subscriptions based on the resolution by Nanoform Finland Plc’s Annual General Meeting 2025 on remuneration of the Board of Directors
Nanoform Finland Plc | Company Release | June 17, 2025…
Nanoform starts Pivotal Human Bioequivalence Studies of Nanoenzalutamide
Nanoform Finland Plc | Press Release | June 12, 2025…
Development of Nanoformed Trastuzumab for Subcutaneous Injection to Be Presented at DDF Summit in Berlin
Nanoform Finland Plc | Press Release | June 03, 2025…
Positive nanoform biologics respiratory data to be presented at drug delivery and formulation summit
Nanoform Finland Plc | Press Release | May 28, 2025…
Nanoform Q1 2025 report: Deal mosaic emerge and commercial value clearly seen in our CESS® technology
Nanoform Finland Plc | Company Release | May 20, 2025…
Inside information made public: Nanoform partners with two specialist healthcare investors to develop and commercialise Nanoencorafenib
Nanoform Finland Plc | Inside Information | May 20, 2025…
Invitation to Nanoform’s Q1 2025 Report Presentation
Nanoform Finland Plc | Press Release | May 06, 2025…
Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc
Company release Nanoform Finland Plc April 15, 2025 14.10 Finnish…
Resolutions of Nanoform Finland Plc’s Annual General Meeting on April 15, 2025
Company release Nanoform Finland Plc April 15, 2025 14.00 Finnish…
Notice to the Annual General Meeting of NANOFORM FINLAND Plc
Notice to the Annual General Meeting of NANOFORM FINLAND Plc…
Kutsu Nanoform Finland Oyj:n varsinaiseen yhtiökokoukseen
Kutsu Nanoform Finland Oyj:n varsinaiseen yhtiökokoukseen Nanoform Finland Oyj:n (”Yhtiö”)…
Nanoform 2024 report: Deal discussions around product kernels intensify
Company Announcement Nanoform Finland Plc February 27, 2025 08:10 a.m.…
Invitation to Nanoform’s Q4 and FY 2024 Report Presentation
Press release Nanoform Finland Plc February 13, 2025 11:00 a.m.…